Schrodinger Turns Profit, Shifts to Hosted Model by 2028

Schrodinger (SDGR) reported its fiscal 2025 Q4 earnings on Feb 25th, 2026, with results that exceeded expectations and signaled a strategic shift toward hosted revenue. The company returned to profitability with EPS of $0.44 and net income of $32.51 million, reversing a 2024 Q4 net loss of $40.22 million. Management outlined a 75% transition to a hosted model by 2028, which will reshape revenue recognition but is expected to drive long-term growth.

Revenue

Schrodinger’s total revenue declined 1.2% year-over-year to $87.23 million in Q4 2025, with drug discovery revenue contributing $56.4 million—a more than doubling from 2024. Software revenue reached $199.5 million, reflecting 11% annual growth despite a quarterly decline due to a shift in revenue recognition timing. The company’s full-year 2025 revenue rose 23% to $256 million, driven by a $200 million software annual contract value (ACV).

Earnings/Net Income

The company’s earnings per share (EPS) surged to $0.44 in Q4 2025, a 350% improvement from a loss of $0.18 in the prior-year period. Net income turned positive at $32.51 million, a 180.8% swing from a $40.22 million loss in 2024 Q4. This turnaround was supported by cost reductions and operational efficiencies. The company’s improved financial performance underscores a strategic pivot toward sustainable profitability.

Price Action

Schrodinger’s stock price edged up 1.64% on the latest trading day but fell 0.08% for the week and 28.14% month-to-date as of Feb 25th, 2026.

Post-Earnings Price Action Review

The strategy of buying Schrodinger shares after its Q4 revenue decline and holding for 30 days yielded a -42.97% return over the past three years, significantly underperforming the 60.55% benchmark. This approach generated an excess return of -103.52% and a compound annual growth rate (CAGR) of -13.79%, highlighting the risks of relying on post-earnings volatility for investment decisions.

CEO Commentary

CEO Ramy Farid emphasized Schrodinger’s 23% total revenue growth in 2025 and a $402 million cash position, positioning the company to fund its hosted model transition. He noted challenges from tight pharmaceutical budgets and biotech capital markets but highlighted near-term catalysts, including phase I clinical trials and new product launches in biologics and predictive toxicology.

Guidance

Schrodinger guided 2026 software ACV to $218 million–$228 million, reflecting 10%–15% growth. The company reiterated its path to positive adjusted EBITDA by 2028, supported by its $400 million cash reserves. However, the hosted transition is expected to create near-term revenue recognition headwinds and margin compression.

Additional News

Within three weeks of the Q4 2025 earnings release, Schrodinger announced key strategic initiatives. The company accelerated its shift to a hosted revenue model, targeting 75% adoption by 2028, which will create short-term revenue recognition challenges but align with long-term margin stability. Additionally, management outlined plans for platform expansion, including new product launches in 2026 focused on biologics and predictive toxicology to diversify its customer base. The CEO highlighted these initiatives as critical to navigating pharma industry budget constraints and capital market challenges.